mor

Anti-PDGFB Antibody (MOR-8457) is a human-derived antibody expressed in CHO cells, targeting PDGFB. It features a huIgG1 heavy chain and a huλ light chain, with an estimated molecular weight (MW) of 145 kDa. For an isotype control, refer to HumanIgG1kappa, Isotype Control.

Felzartamab(MOR-202) is a human-targeted monoclonal antibody to CD38 for the study of multiple myeloma and advanced antibody-mediated rejection of allogeneic kidney transplants.

Otilimab (GSK 3196165) is a humanized monoclonal antibody against granulocyt-macrophage colony-stimulating factor (GM-CSF). Otilimab has anti-inflammatory activity, regulates the biological function of GM-CSF by blocking the interaction between GM-CSF and its cell surface receptors, and can be used in studies to treat severe COVID-19 pneumonia.

Tafasitamab (XmAb5574) is an FC-modified humanized monoclonal antibody targeting the human B-cell surface antigen CD19 for the study of diffuse large B-cell lymphoma.

MOR-106 (MOR12743) is a humanized anti-IL-17C IgG1 monoclonal antibody. It works by specifically binding to IL-17C, thereby inhibiting the NF-κB signaling pathway, with an IC50 of 59 pM for human IL-17C and 55 pM for mouse IL-17C. MOR-106 effectively reduces skin inflammation and related inflammatory factors in animal models of psoriasis and atopic dermatitis.

MOR101 is a humanized monoclonal antibody inhibitor targeting ICAM-1/CD54. It is applicable in the study of both acute and chronic inflammation, such as in cases of burns.

Anti-MST1R Antibody (MOR07692) is a humanized IgG1 monoclonal antibody specifically targeting MST1R.

Semorinemab (RG6100) is a humanised monoclonal antibody targeting the N-terminal domain of tau protein with a Kd of 3.8 nM, suitable for Alzheimer's disease research. It binds all six human tau isoforms and reduces tau accumulation.

Morolimumab, an IgG1 human monoclonal antibody targeting RHD/CD240D, serves as a research tool for immune diseases [1].

Efmoroctocog alfa, a recombinant human coagulation factor VIII-Fc fusion protein (rFVIIIFc), serves as a therapeutic agent for Hemophilia A research [1].

The Anti-TMEFF1/Tomoregulin-1 Antibody is a human-derived antibody expressed in CHO, targeting TMEFF1/Tomoregulin-1. It possesses a huIgG1 heavy chain and a huκ light chain, with an estimated molecular weight (MW) of 150 kDa. For isotype control, refer to HumanIgG1kappa, Isotype Control.

MORAb-028 is a humanized IgG1 monoclonal antibody inhibitor targeting GD2. It exhibits potent antitumor activity by killing GD2-expressing target cells through complement-dependent cytotoxicity (CDC). In EL-4-luc xenograft mouse models, MORAb-028 significantly reduces tumor growth. This compound is applicable for melanoma cancer research.

MORAb-066 is a human monoclonal antibody (mAb) targeting CD142/F3/TF. It is applicable in research related to breast cancer, colorectal cancer, non-small cell lung cancer, and pancreatic cancer.

Infliximab is a monoclonal antibody, a human-mouse chimeric monoclonal antibody that inhibits TNF-α and prevents TNF-α from interacting with TNFR1 and TNFR2. Infliximab can be used to treat Crohn's disease and rheumatoid arthritis.

Panitumumab is a fully human IgG2 monoclonal antibody targeting the epidermal growth factor receptor EGFR).

Gimsilumab (MORAb-022) is a humanized monoclonal antibody targeting granulocyte macrophage colony-stimulating factor for the study of COVID-19-induced inflammation and hypoxemia.

Amatuximab (MORab-009) is a humanized chimeric IgG1/k monoclonal antibody targeting cell surface mesothelin (MSLN) with antitumor activity for the treatment of solid tumors.

Farletuzumab (MORAb-003) is a humanized monoclonal antibody with a high affinity for folate receptor-α (FRα), acting as a potent inhibitor of FRα and impeding the growth of cells that overexpress this receptor, making it useful for cancer research.

Ontuxizumab (MORAb-004) is a potent IgG1/κ monoclonal antibody targeting endomelanic acid with anti-tumor effects. It specifically targets endothelin (TEM-1 or CD248) and is used for the treatment of metastatic melanoma.

Farletuzumab ecteribulin (MORAb-202) is a highly cytotoxic antibody-drug conjugate (ADC) targeting human folate receptor alpha (FRA). This ADC comprises the humanized Farletuzumab antibody linked to Mal-PEG2-Val-Cit-PAB-eribulin through reduced interchain disulfide bonds, with an agent-to-antibody ratio of 4.0, demonstrating potent antitumor activity against FRA-positive cells in vitro.

Daratumumab is a human monoclonal antibody that targets CD38 a cell surface protein that is overexpressed on multiple myeloma MM) cells.

Matuzumab (EMD 72000) is a humanized monoclonal antibody targeting EGFR with potential anticancer activity that blocks EGFR activation and downstream signaling for the study of non-small cell lung cancer.